A peptide-centric approach to breast cancer biomarker discovery utilizing label-free multiple reaction monitoring mass spectrometry

2008 ◽  
Vol 3 (1) ◽  
pp. 78-82 ◽  
Author(s):  
Gergana Metodieva ◽  
Christina Greenwood ◽  
Louise Alldridge ◽  
Paul Sauven ◽  
Metodi Metodiev
Keyword(s):  
Breast Cancer ◽  
Mass Spectrometry ◽  
Biomarker Discovery ◽  
Multiple Reaction Monitoring ◽  
Cancer Biomarker ◽  
Reaction Monitoring ◽  
Label Free

Quantitative analysis of genetically modified soya using multiple reaction monitoring mass spectrometry with endogenous peptides as internal standards

2018 ◽  
Vol 25 (1) ◽  
pp. 50-57 ◽  
Author(s):  
Shobha Devi ◽  
Yi-Cheng Lin ◽  
Yen-Peng Ho
Keyword(s):  
Mass Spectrometry ◽  
Genetically Modified ◽  
Multiple Reaction Monitoring ◽  
Linear Regression Analysis ◽  
Exchange Chromatography ◽  
Protein Quantification ◽  
Reaction Monitoring ◽  
Label Free ◽  
Internal Standards ◽  
Phosphate Synthase

A simple label-free method was developed for the quantification of the herbicide-resistant gene-related protein 5-enolpyruvylshikimate-3-phosphate synthase using multiple reaction monitoring liquid chromatography–mass spectrometry. Sample pretreatment procedures including ion exchange chromatography and CaCl2 precipitation were used to purify the 5-enolpyruvylshikimate-3-phosphate synthase protein. Quantification of various percentages of genetically modified soya (0.5–100%) was performed by selecting suitable endogenous soybean peptides as internal standards. Results indicated that Gly P (QGDVFVVPR) and Lec P (LQLNK) are useful internal standards for the quantification of low and high percentages of genetically modified soya, respectively. Linear regression analysis of both calibration curves yielded good linearity with R2 of 0.99. This approach is a convenient and accurate quantification method for genetically modified soya at a level as low as 0.5% (less than the current EU threshold for labeling genetically modified soya).

scholarly journals Clinical Application of Multiple Reaction Monitoring-Mass Spectrometry to Human Epidermal Growth Factor Receptor 2 Measurements as a Potential Diagnostic Tool for Breast Cancer Therapy

2020 ◽  
Vol 66 (10) ◽  
pp. 1339-1348
Author(s):  
Misol Do ◽  
Hyunsoo Kim ◽  
Injoon Yeo ◽  
Jihyeon Lee ◽  
In Ae Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mass Spectrometry ◽  
Multiple Reaction Monitoring ◽  
Growth Factor Receptor ◽  
Specific Protein ◽  
Her2 Status ◽  
Reaction Monitoring ◽  
Her2 Expression ◽  
Expression Levels ◽  
Epidermal Growth

Abstract Background Human epidermal growth factor receptor 2 (HER2) is often overexpressed in breast cancer and correlates with a worse prognosis. Thus, the accurate detection of HER2 is crucial for providing the appropriate measures for patients. However, the current techniques used to detect HER2 status, immunohistochemistry and fluorescence in situ hybridization (FISH), have limitations. Specifically, FISH, which is mandatory for arbitrating 2+ cases, is time-consuming and costly. To address this shortcoming, we established a multiple reaction monitoring-mass spectrometry (MRM-MS) assay that improves on existing methods for differentiating HER2 status. Methods We quantified HER2 expression levels in 210 breast cancer formalin-fixed paraffin-embedded (FFPE) tissue samples by MRM-MS. We aimed to improve the accuracy and precision of HER2 quantification by simplifying the sample preparation through predicting the number of FFPE slides required to ensure an adequate amount of protein and using the expression levels of an epithelial cell-specific protein as a normalization factor when measuring HER2 expression levels. Results To assess the correlation between MRM-MS and IHC/FISH data, HER2 quantitative data from MRM-MS were divided by the expression levels of junctional adhesion molecule A, an epithelial cell-specific protein, prior to statistical analysis. The normalized HER2 amounts distinguished between HER2 2+/FISH-negative and 2+/FISH-positive groups (AUROC = 0.908), which could not be differentiated by IHC. In addition, all HER2 status were discriminated by MRM-MS. Conclusions This MRM-MS assay yields more accurate HER2 expression levels relative to immunohistochemistry and should help to guide clinicians toward the proper treatment for breast cancer patients, based on their HER2 expression.

Chemical profiling of cerebrospinal fluid by multiple reaction monitoring mass spectrometry

The Analyst ◽  
2016 ◽  
Vol 141 (18) ◽  
pp. 5252-5255 ◽  
Author(s):  
Christina R. Ferreira ◽  
Karen E. Yannell ◽  
Brit Mollenhauer ◽  
Ryan D. Espy ◽  
Fernanda B. Cordeiro ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Cerebrospinal Fluid ◽  
Biomarker Discovery ◽  
Multiple Reaction Monitoring ◽  
Reaction Monitoring ◽  
Chemical Profiling

We report an accelerated biomarker discovery workflow and results of sample screening by mass spectrometry based on multiple reaction monitoring (MRM).

A Combined Shotgun and Targeted Mass Spectrometry Strategy for Breast Cancer Biomarker Discovery

2015 ◽  
Vol 14 (7) ◽  
pp. 2807-2818 ◽  
Author(s):  
Martin Sjöström ◽  
Reto Ossola ◽  
Thomas Breslin ◽  
Oliver Rinner ◽  
Lars Malmström ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mass Spectrometry ◽  
Biomarker Discovery ◽  
Cancer Biomarker
Sign in / Sign up

Export Citation Format

Share Document